Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Current Leases (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Current Leases data on record, last reported at $618000.0 in Q3 2025.

  • For Q3 2025, Current Leases rose 60.94% year-over-year to $618000.0; the TTM value through Sep 2025 reached $618000.0, up 60.94%, while the annual FY2024 figure was $785000.0, 41.19% up from the prior year.
  • Current Leases reached $618000.0 in Q3 2025 per ZBIO's latest filing, down from $793000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $908000.0 in Q1 2025 and bottomed at $384000.0 in Q3 2024.
  • Average Current Leases over 3 years is $674000.0, with a median of $701500.0 recorded in 2024.
  • Peak YoY movement for Current Leases: surged 41.19% in 2024, then surged 60.94% in 2025.
  • A 3-year view of Current Leases shows it stood at $556000.0 in 2023, then soared by 41.19% to $785000.0 in 2024, then fell by 21.27% to $618000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $618000.0 in Q3 2025, $793000.0 in Q2 2025, and $908000.0 in Q1 2025.